Board of Directors2018-12-13T22:03:51+00:00

Board of Directors

Steve Engle – Non-Executive Chairman

Steve Engle on the Prescient Therapeutics Board of Directors

Steve Engle is CEO of Averigon Consulting, an advisory firm to the life science industry. Previously, Mr. Engle was Chairman and CEO of XOMA, a developer of antibody therapeutics for inflammatory, metabolic, oncology and other diseases. Prior to that, he was Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. Mr. Engle served as VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. He was VP of Marketing at a $50 million device company and a management consultant at Strategic Decisions Group and SRI (Stanford Research Institute) International.

Mr. Engle is a board member of Prescient Therapeutics, AROA Biosurgery, a developer of regenerative medicine products, and Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. Mr. Engle is a former board member of BIO, Baybio, and BIOCOM, and the Lupus Foundation of America. Mr. Engle holds a B.S. and an M.S. in electrical engineering with a focus in biomedical engineering from the University of Texas at Austin.

Steven Yatomi-Clarke – CEO and Managing Director

Steven Yatomi-Clarke Prescient Therapeutics Board of Directors

Steven Yatomi-Clarke has a distinguished career in the Australian capital markets with a particular focus on the life sciences sector, where he has played a leading role as both a corporate advisor and fund raiser to many biotechnology companies.  Mr Yatomi-Clarke previously held a position as a Director in Corporate Finance at Patersons Securities.

Educated at the University of Melbourne, where he earned a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, he has the rare distinction of readily bridging the divide between science and commerce.

He has a strong track record of financing multiple private and public biotechnology companies, bringing more than 15 years’ experience in investment banking with a particular focus on the life sciences/biotechnology sector.

Mr Yatomi-Clarke has consistently been one of the country’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments for medical device and pharmaceutical companies.

Paul Hopper – Executive Director

Paul Hopper is on Prescient Therapeutics Board of Directors

Mr Hopper has international & ASX biotech capital markets experience, particularly in oncology. He is the former Chairman of Viralytics (acquired in June 2018 by Merck for $500m), Founder & Director of Prescient, Founder of Imugene & Polynoma LLC, former Director pSivida, Somnomed & Fibrocell Science.

Dr James Campbell – Non-Executive Director

Dr James Campbell Prescient Therapeutics Board of Directors

Dr James Campbell brings to Prescient a solid track record as a scientist and commercial executive. He was previously the Chief Financial Officer and Chief Operating Officer of Chemgenex, which was acquired by Cephalon for $230 million in 2011.

His responsibilities ranged from IP management to licensing and business development and as a member of the executive team, he helped steer and transform the company from a $10 million research based entity to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA before its $230 million sale.

More recently he guided the creation of Invion Limited (ASX: IVX) as a non-executive director and retains this role.

Dr Campbell also has experience advising private biotechnology companies in the US and New Zealand with capital raisings and partnering negotiations.